News - Onyx Pharmaceuticals


Current filters:

Onyx Pharmaceuticals

Popular Filters

1 to 25 of 35 results

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan


There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019


The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Bayer files for EU approval of regorafenib for GIST


German pharma major Bayer (BAYN: DE) said this morning (September 5) that it has submitted an application…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationStivarga

Bayer and Onyx' Stivarga cleared in Europe


In a second piece of good news within a couple of days for German drug major Bayer (BAYN: DE), the European…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Nexavar gains FDA priority review for thyroid cancer sNDA


German drug major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), which has just agreed…

BayerBiotechnologyNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Onyx Pharma accepts increased bid from Amgen


Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

Onyx partners for carfilzomib managed access program in Europe


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) is partnering with UK-based Idis Limited to initiate…

carfilzomibEuropeIdis LimitedMarkets & MarketingOncologyOnyx PharmaceuticalsPharmaceutical

Onyx Pharma rejects Amgen's unsolicited $120 per share takeover offer


Following a day of speculation and rumor on Friday, US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX)…

AmgenBayerBiotechnologyCelgeneMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizerRoche

Onyx enter strategic alliance focused on advancing drug discovery and development


US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and the University of California, San Francisco (UCSF)…

BiotechnologyOncologyOnyx PharmaceuticalsResearch

Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's talimogene laherparepvec


The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend…

AfinitorAmgenBayerBiotechnologyNexavarNovartisOncologyOnyx PharmaceuticalsPharmaceuticalResearchtalimogene laherparepvec

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma


US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

FDA expands use of Bayer and Onyx' Stivarga for advanced GIST


The US Food and Drug Administration yesterday expanded the approved use of German drug major Bayer's…

BayerNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar


US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

Positive Ph III results for Bayer's Nexavar in thyroid cancer


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) this morning revealed…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

Bayer's Stivarga races to FDA approval on the heels of Zaltrap


The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Bayer files NDA for regorafenib for the treatment of GIST


The US subsidiary of Germany's Bayer (BAYB: DE) has submitted a New Drug Application to the US Food and…

BayerBiotechnologyNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulation

Onyx soars as FDA approves Kyprolis for multiple myeloma


Shares of US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) leapt 11.7% to $76.38 on Friday, after…

BiotechnologyKyprolisNorth AmericaOncologyOnyx PharmaceuticalsRegulation

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer


A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

News briefs: US priority review for regorafenib; Ph IIb blisibimod data


Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

Batch of mixed opinions from FDA advisory panels


Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

Onyx Pharma links with Texas MD Anderson Cancer Center on research


US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center…

BiotechnologycarfilzomibOncologyOnyx PharmaceuticalsoprozomibResearch

Bayer and Onyx' Nexavar fails in Ph III lung cancer study


There was disappointment for German drug major Bayer (BAYB: DE) and partner Onyx Pharmaceuticals (Nasdaq:…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

1 to 25 of 35 results

Back to top